Abstract
In this study, a Pt(IV)-Au(I)-gemcitabine prodrug that co-releases oxaliplatin, a redox active gold N-heterocyclic carbene (NHC) and gemcitabine upon intracellular reduction is reported. Relative to its constituents, this prodrug displays improved cytotoxicity, metal uptake and an in vitro immunogenic cell death response.